Defibrotide sodium

N/A

Report date: 2026/04/09 20:00:21
First In Class

Base Information

Drug NameDefibrotide sodium
Drug Alias Name去纤苷defibrotidadefibrotidum去纤苷酸钠Defibrotide +[10] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionVon willebrand factor inhibitorsPlasminogen activator inhibitor 1 inhibitorsThrombomodulin stimulants
TargetsVon willebrand factorPlasminogen activator inhibitor 1Thrombomodulin
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Bone marrow transplant rejectionThrombotic Microangiopathies +[13] 
Global Approved IndicationsHepatic Veno-Occlusive Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2013/10/18
Country/TerritoryBelgiumCanadaUnited States +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGentium SrlJazz Pharmaceuticals Plc
China Registration ClassN/A

Develop Information

Active CompaniesThe Brigham and Women's HospitalGentium SrlJohns Hopkins University +[8] 
Inactive CompaniesDana-Farber Cancer InstituteUniversity Of California San FranciscoLoyola University
Active IndicationsCoronavirus Disease 2019 (COVID-19)Anemia, Sickle CellMucocutaneous Lymph Node Syndrome +[5] 
Inactive IndicationsBone marrow transplant rejectionThrombotic MicroangiopathiesHeart Diseases +[8] 

Other Information

ATC CodeB01AX01
Related LinksWikipediaDrugBankKEGG